Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer
Not Applicable
- Conditions
- Breast Cancer
- Registration Number
- NCT00538330
- Brief Summary
Post operative adjuvant chemotherapy followed by adjuvant Tamoxifen vs nil for patients with operable breast cancer
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
- Patients with operable breast cancer
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method safety 10 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does adjuvant chemotherapy plus Tamoxifen modulate estrogen receptor signaling in operable breast cancer (NCT00538330)?
What is the comparative efficacy of chemo-Tamoxifen vs aromatase inhibitors in ER+/HER2- breast cancer (NCT00538330)?
Which biomarkers correlate with improved outcomes in NCT00538330 chemo-Tamoxifen combination therapy?
What are the long-term adverse event profiles of adjuvant chemo-Tamoxifen in NCT00538330 compared to no treatment?
How do CDK4/6 inhibitors compare to Tamoxifen in combination with chemotherapy for operable breast cancer (NCT00538330)?